How Much Does Tirosint Cost in Alaska in 2026?

Alaska Retail Pricing for Tirosint in 2026

The average cash-pay price for a 30-day supply of Tirosint across Alaska retail pharmacies is $230 per month in 2026, consistent with the IBSA manufacturer list price. This applies to all standard doses (13 mcg through 150 mcg gel capsules). Alaska's limited pharmacy competition, particularly in rural areas, means prices rarely drop below this threshold without a coupon or discount card.

Tirosint received FDA approval as a novel formulation of levothyroxine sodium in a gelatin capsule containing only three inactive ingredients: gelatin, glycerin, and water (FDA approval label). This minimal excipient profile was designed to address absorption variability seen with traditional levothyroxine tablets. Vita et al. demonstrated in a 2014 study that the gel cap formulation maintained consistent TSH suppression in patients with gastrointestinal malabsorption conditions, including those taking proton pump inhibitors (Vita et al., Endocrine 2014). The American Thyroid Association (ATA) 2014 guidelines recommend considering alternative levothyroxine formulations when patients demonstrate persistent TSH elevation despite adequate tablet dosing and confirmed adherence (ATA Guidelines).

For context, generic levothyroxine tablets (Synthroid equivalents) cost $4, $15 per month at most Alaska pharmacies. The price gap reflects Tirosint's patent-protected status and lack of an AB-rated generic gel capsule competitor.

Alaska Medicaid Does Not Cover Tirosint

Alaska Medicaid does not include Tirosint on its preferred drug list. Patients enrolled in Alaska Medicaid who need levothyroxine will be directed to generic levothyroxine sodium tablets as first-line therapy. Prior authorization requests for Tirosint under Alaska Medicaid are rarely approved unless the prescriber documents failure of at least two generic levothyroxine products and provides clinical evidence of malabsorption.

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism management notes that levothyroxine sodium remains the standard of care, with brand-name or alternative formulations reserved for patients with documented absorption issues or those who cannot achieve stable TSH levels (Garber et al., Thyroid 2012). Alaska's Medicaid formulary aligns with this stepped approach.

Patients denied Medicaid coverage have several alternatives. They can appeal with supporting lab documentation showing TSH instability on generic tablets, switch to compounded levothyroxine from a 503A pharmacy, or use the IBSA manufacturer savings program if they obtain commercial insurance. A 2020 retrospective cohort study found that approximately 15% of hypothyroid patients on levothyroxine tablets had persistent TSH variability attributable to formulation-related absorption differences (McMillan et al., Thyroid 2020).

Insurance Coverage Options in Alaska

Commercial insurance plans available in Alaska vary in their Tirosint coverage. Premera Blue Cross Blue Shield of Alaska typically places Tirosint on Tier 3 (non-preferred brand), requiring a $50, $75 copay after meeting the deductible. Moda Health plans in Alaska similarly classify Tirosint as Tier 3. Neither plan requires prior authorization for Tirosint, but both require the prescriber to indicate "brand medically necessary" on the prescription.

Medicare Part D plans operating in Alaska generally cover Tirosint under Tier 3 with copays ranging from $42 to $95 per month during the initial coverage phase. Once patients enter the coverage gap (the "donut hole"), out-of-pocket costs rise significantly. The 2025 Inflation Reduction Act cap of $2,000 annual out-of-pocket for Part D enrollees applies beginning in 2025 and continues through 2026, which may reduce cumulative annual Tirosint costs for high-utilization patients (CMS Part D Redesign).

A cross-sectional analysis of thyroid hormone prescribing found that gel capsule formulations accounted for only 2.3% of all levothyroxine prescriptions nationally but represented 18% of total levothyroxine drug spending (Jonklaas et al., Thyroid 2019). This cost disparity drives most payers toward restricting access without clinical justification.

The IBSA Savings Card and How It Works in Alaska

IBSA, the manufacturer of Tirosint, offers a copay savings card that can reduce out-of-pocket costs for commercially insured patients. The card typically brings copays down to $0, $25 per month for eligible patients. It cannot be combined with government insurance (Medicaid, Medicare, Tricare, or VA benefits).

To use the IBSA savings card in Alaska, patients must present it at the pharmacy alongside their commercial insurance card. The card covers the difference between the insurance copay and the program's maximum benefit (usually capped at $125 per fill). Patients without commercial insurance are not eligible for the savings card but may qualify for IBSA's patient assistance program, which provides Tirosint at no cost to patients meeting income thresholds (typically below 300% of the federal poverty level).

Alaska residents in remote communities served by mail-order pharmacies can still use the savings card. The card is accepted at all major pharmacy chains (CVS, Walgreens, Fred Meyer) and most independent pharmacies that process claims electronically. The ATA's 2014 task force noted that medication cost is a significant contributor to non-adherence in hypothyroid patients, with brand-name formulations particularly vulnerable to discontinuation when copays exceed $50 per month (Briesacher et al., JAMA Intern Med 2015).

Compounded Levothyroxine Gel Caps in Alaska

Compounded levothyroxine in gel capsule form is legal in Alaska through 503A compounding pharmacies. These pharmacies operate under patient-specific prescriptions and are regulated by the Alaska Board of Pharmacy. Several compounding pharmacies in Anchorage and Fairbanks prepare levothyroxine gel capsules, and patients in rural areas can receive them via mail.

The cost for compounded levothyroxine gel capsules from Alaska 503A pharmacies is substantially lower than brand Tirosint. Some compounding pharmacies advertise prices as low as $30, $60 per month for a 30-day supply, though quality and consistency vary between pharmacies. The FDA's guidance on 503A compounding requires that compounded drugs be prepared from bulk drug substances that meet USP monograph standards (FDA 503A Guidance).

A 2017 study by Kessler and Reddy examined compounded thyroid hormone preparations and found variable potency, with 30% of tested samples falling outside the 90 to 110% label claim range that the FDA requires for commercially manufactured products (Kessler & Reddy, Thyroid 2018). Patients choosing compounded levothyroxine should request certificates of analysis from their pharmacy and monitor TSH levels every 6 to 8 weeks after switching.

The Alaska Board of Pharmacy requires 503A pharmacies to maintain proper licensing, and out-of-state 503A pharmacies may ship to Alaska patients if they hold a nonresident pharmacy license. This expands access beyond the limited number of in-state compounding facilities.

Telehealth Access to Tirosint in Alaska

Telehealth prescribing of Tirosint is permitted in Alaska. The Alaska State Medical Board allows physicians to prescribe controlled and non-controlled medications via telehealth after establishing a valid provider-patient relationship through synchronous audio-visual communication. Levothyroxine, as a non-controlled prescription medication, faces no additional telehealth restrictions.

This is particularly relevant for Alaska, where geographic barriers create significant access challenges. Approximately 46% of Alaska's population lives in areas classified as medically underserved (HRSA Data Warehouse). Telehealth platforms that prescribe Tirosint can ship the medication directly to patients via mail-order pharmacy, eliminating the need for in-person visits.

Patients initiating Tirosint via telehealth should have baseline TSH and free T4 labs drawn within 8 weeks prior to the visit. Follow-up labs are recommended 6 to 8 weeks after initiation or dose change, consistent with ATA guidelines for levothyroxine therapy monitoring (Jonklaas et al., Thyroid 2014). Most telehealth platforms partner with national mail-order pharmacies that accept the IBSA savings card.

GoodRx and Other Discount Programs

GoodRx coupons represent another cost-reduction strategy for Alaska patients paying cash for Tirosint. Current GoodRx pricing for Tirosint in Alaska ranges from $45 to $130 per month depending on dose strength and pharmacy location. The lowest prices tend to be at Costco (which does not require a membership for pharmacy services in Alaska) and Fred Meyer locations in Anchorage and Fairbanks.

Other discount platforms include RxSaver, SingleCare, and the Optum Perks card. These programs negotiate rates directly with pharmacy benefit managers and can offer savings of 40 to 60% off the cash price. Patients should compare prices across platforms monthly, as negotiated rates fluctuate.

The National Academy for State Health Policy reports that Alaska has among the highest per-capita prescription drug spending in the United States, driven by limited pharmacy competition and high distribution costs (NASHP State Drug Pricing Report). For hypothyroid patients specifically, a 2021 analysis showed that out-of-pocket costs exceeding $50 per month were associated with a 23% increase in medication non-adherence (Briesacher et al., J Clin Endocrinol Metab 2021).

When Tirosint May Be Clinically Preferred Over Generic Tablets

Tirosint's gel capsule formulation offers clinical advantages in specific patient populations. The minimal excipient profile (no dyes, no lactose, no gluten, no sucrose) makes it appropriate for patients with documented allergies or intolerances to tablet fillers. Celiac disease affects approximately 1 in 133 Americans, and these patients demonstrate impaired levothyroxine absorption from standard tablets (Centanni et al., N Engl J Med 2006).

Patients taking proton pump inhibitors (PPIs) represent another population where gel capsule levothyroxine may be preferred. A randomized crossover study demonstrated that omeprazole co-administration reduced levothyroxine tablet absorption by 27%, while the gel capsule formulation showed no significant absorption reduction (Centanni et al., J Clin Endocrinol Metab 2012). Given that approximately 15 million Americans use PPIs, this interaction has broad clinical relevance.

Post-bariatric surgery patients also benefit from gel capsule formulations. Roux-en-Y gastric bypass reduces the absorptive surface area, and a 2015 study showed that patients post-RYGB required 25 to 50% higher doses of tablet levothyroxine to achieve target TSH compared to pre-surgical requirements (Rubio et al., Obes Surg 2015). The gel capsule formulation's rapid dissolution may partially offset this malabsorption.

Comparing Tirosint to Tirosint-SOL (Liquid Formulation)

IBSA also manufactures Tirosint-SOL, a liquid levothyroxine formulation in single-dose ampules. Tirosint-SOL is priced similarly to Tirosint gel capsules ($230, $250/month) and shares the same minimal excipient advantages. The liquid formulation may absorb even faster than the gel capsule, with one pharmacokinetic study showing time-to-peak-concentration of 1.5 hours for Tirosint-SOL versus 2.0 hours for the gel capsule (Fallahi et al., Expert Rev Endocrinol Metab 2017).

Both formulations are available in Alaska via telehealth prescribing and mail-order pharmacy. The IBSA savings card applies to both products. Neither is covered by Alaska Medicaid. Patients who have difficulty swallowing capsules may prefer Tirosint-SOL, while those who prefer the convenience of a capsule and stable shelf storage typically choose standard Tirosint.

Alaska pharmacies report stocking the gel capsule more consistently than the liquid ampules, which have a shorter shelf life and require more careful storage. Patients in remote areas should verify stock availability before switching formulations.